Straits Times Index
3,212.64 -6.36 (-0.20%) Nikkei
27,385.25 -34.36 (-0.13%) Hang Seng
19,915.68 -133.96 (-0.67%) FTSE 100
7,405.45 -94.15 (-1.26%) BTC-USD
27,688.89 -578.16 (-2.05%) CMC Crypto 200
602.08 -16.30 (-2.64%)
VRTX Jan 2024 120.000 put
| Previous close | 2.3000 |
| Open | 6.6100 |
| Bid | 1.3000 |
| Ask | 9.6000 |
| Strike | 120.00 |
| Expiry date | 2024-01-19 |
| Day's range | 2.3000 - 2.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 77 |
- Zacks
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.
- Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.
